The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Alcon has suffered with its LADARVision system recalls and lawsuits, and has looked particularly troubled following AMO's acquisition of VISX. Although AMO/VISX remains the market leader for refractive correction, the Allegretto represents new technology with potential advantages in terms of accuracy...
This article reports that the FDA approved an Investigative New Drug application for an anti-integrin (JSM 6427) in the treatment of age-related macular degeneration (AMD). This would allow testing in preclinical trials of this compound for neovascular AMD. This could be another medication...
The FDA has just approved a "bifocal LASIK" technique from Advanced Medical Optics using their CustomVue Excimer laser platform. It has been approved as " a new device". In actuality, it is neither a new device nor does it provide bifocal vision.
The FDA recently approved a CustomVue Monovision LASIK surgery (AMO; EYE) for the treatment of presbyopia. The premise is to treat one eye for distance and allow the other (partially treated) for near vision reducing the need for spectacles. This is nothing new and has been used for years as ...
AMO (EYE) recently outbid a private equity firm to acquire Bausch & Lomb (BOL). It has the potential to add to AMO's market share and establish it as the force in Ophthalmology.
Currently the ophthalmic device market is organized into an oligopoly including Alcon, AMO and Bausch. AMO has shown fairly dramatic growth with its acquisition of VISX, Intralase and Wavefront Sciences. However, AMO's potential acquisition of Bausch is on a grander scale. There are...
In this news release presented today, this leading ophthalmic journal reports that AMO has presented the highest bid for the purchase of Bausch and Lomb.
Dr Smiddy reviewed age-related macular degeneration studies to evaluate the cost for the visual benefit of various treatment approaches, and then compared them with the costs for treating other retinal conditions. This study founds costs for treating wet macular degeneation could be as high as $9000...
In a study of patients with choroidal neovascularization due to age-related macular degeneration, Lazic and Gabric demonstrated that improvements in vision and reduction of central macular thickness after one month and their maintenance over three months are more significant after verteporfin photodynamic...
The European Eye Study (EUREYE) investigated 4,750 randomly sampled people over age 65 and examined the association between cigarette smoking and age-related macular degeneration and concluded that there is a postive correlation to smoking and blindness from macular degeneration.